Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Frazier, Marcadia founders reunite for rare endocrine diseases in MBX’s $34.6M A round

MBX is applying peptide optimization tech from an Indiana University lab to rare endocrine disorders

Kent Hawryluk and Richard DiMarchi are following up on the first two companies they formed together, diabetes-focused Marcadia and MB2, with rare endocrine diseases play MBX Biosciences.

Frazier, which led Marcadia Biotech Inc.’s series A round, also led MBX Biosciences Inc.’s $34.6 million series A. Other participants in the Indiana-based company’s financing, which includes

Read the full 540 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers